Navidea Biopharmaceuticals (NAVB) Competitors $0.0005 0.00 (0.00%) As of 03:53 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsShort InterestTrendsBuy This Stock NAVB vs. VINC, MYMD, NCNA, SYRS, OBSV, SCPS, SMFL, VRPX, STAB, and EVLOShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Vincerx Pharma (VINC), MyMD Pharmaceuticals (MYMD), NuCana (NCNA), Syros Pharmaceuticals (SYRS), ObsEva (OBSV), Scopus BioPharma (SCPS), Smart for Life (SMFL), Virpax Pharmaceuticals (VRPX), Statera Biopharma (STAB), and Evelo Biosciences (EVLO). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. Its Competitors Vincerx Pharma MyMD Pharmaceuticals NuCana Syros Pharmaceuticals ObsEva Scopus BioPharma Smart for Life Virpax Pharmaceuticals Statera Biopharma Evelo Biosciences Navidea Biopharmaceuticals (NYSE:NAVB) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation. Does the media favor NAVB or VINC? In the previous week, Vincerx Pharma had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 1 mentions for Vincerx Pharma and 0 mentions for Navidea Biopharmaceuticals. Vincerx Pharma's average media sentiment score of 1.00 beat Navidea Biopharmaceuticals' score of 0.00 indicating that Vincerx Pharma is being referred to more favorably in the news media. Company Overall Sentiment Navidea Biopharmaceuticals Neutral Vincerx Pharma Positive Do analysts prefer NAVB or VINC? Vincerx Pharma has a consensus target price of $40.00, indicating a potential upside of 101,681.17%. Given Vincerx Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Vincerx Pharma is more favorable than Navidea Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Navidea Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is NAVB or VINC more profitable? Navidea Biopharmaceuticals' return on equity of 0.00% beat Vincerx Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Navidea BiopharmaceuticalsN/A N/A N/A Vincerx Pharma N/A -248.33%-132.73% Which has preferable valuation & earnings, NAVB or VINC? Navidea Biopharmaceuticals has higher revenue and earnings than Vincerx Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavidea Biopharmaceuticals$8.13K6.16-$15.18MN/AN/AVincerx PharmaN/AN/A-$40.16M-$20.600.00 Do insiders and institutionals believe in NAVB or VINC? 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, NAVB or VINC? Navidea Biopharmaceuticals has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. SummaryNavidea Biopharmaceuticals and Vincerx Pharma tied by winning 6 of the 12 factors compared between the two stocks. Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$50K$23.79M$5.79B$21.48BDividend YieldN/AN/A5.69%3.53%P/E RatioN/AN/A74.5929.70Price / Sales6.1619.95453.5451.37Price / CashN/AN/A37.0824.52Price / BookN/AN/A12.154.58Net Income-$15.18M-$19.12M$3.28B$1.00B7 Day PerformanceN/A8.99%0.99%0.66%1 Month PerformanceN/A5.82%7.21%4.64%1 Year PerformanceN/A-6.28%63.07%15.96% Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-50.0%$50K$8.13K0.0010VINCVincerx Pharma3.1557 of 5 stars$0.03-7.7%$40.00+133,233.3%-99.7%$157KN/A0.0060Short Interest ↓MYMDMyMD PharmaceuticalsN/A$0.05-21.6%N/AN/A$114KN/A0.006Gap DownHigh Trading VolumeNCNANuCana1.3225 of 5 stars$2.98-6.6%$5,000.00+167,685.2%-99.3%$89KN/A0.0030Positive NewsSYRSSyros Pharmaceuticals4.2817 of 5 stars$0.00+10.0%$1.00+45,354.5%-99.9%$59K$386K0.00120Short Interest ↓Gap DownOBSVObsEvaN/A$0.00+400.0%N/AN/A$39KN/A0.0050SCPSScopus BioPharmaN/A$0.00+33.3%N/AN/A$17KN/A0.009SMFLSmart for LifeN/A$0.00-72.8%N/A-99.9%$16K$11.11M0.00110Gap DownVRPXVirpax Pharmaceuticals0.1889 of 5 stars$0.01flatN/A-99.9%$14KN/A0.007STABStatera BiopharmaN/A$0.00+100.0%N/A+0.0%$11KN/A0.0020Gap DownHigh Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/A-97.8%$9KN/A0.00120 Related Companies and Tools Related Companies Vincerx Pharma Competitors MyMD Pharmaceuticals Competitors NuCana Competitors Syros Pharmaceuticals Competitors ObsEva Competitors Scopus BioPharma Competitors Smart for Life Competitors Virpax Pharmaceuticals Competitors Statera Biopharma Competitors Evelo Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NAVB) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAVB Stock Alerts